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Green tea [Camellia sinensis (L.) O. KUNTZE, Theaceae]
has a longstanding reputation in Asia for its health-promot-
ing properties.2) Epidemiological studies have suggested that
the consumption of green tea provides protection against
stomach cancer.3,4) In a rural area of northern Kyushu, Japan,
a decreased risk of stomach cancer was also noted among
cases reporting a high consumption of green tea.5) Numerous
in vitro and in vivo studies on green tea preparations have
demonstrated the antimutagenic, anticarcinogenic, and anti-
oxidant properties of the flavan-3-ols which form the major
portion of soluble tea constituents.2) However, although other
ingredients such as caffeine and flavonol glycosides are also
contained in green tea, there is no report in regard to antipro-
liferative activity-guided fractionation using human stomach
cancer cells.
In the course of our continuing studies on the antiprolifer-
ative principles in plants,6—13) we found that a hot water ex-
tract of green tea leaves inhibits the growth of human stom-
ach cancer (MK-1) cells. This paper deals with the isolation
of the active principles by activity-guided fractionation and
the structure–activity relationship. Further, since reactive oxy-
gen species play an important role in cell death induction,14)
radical scavenging activity15,16) of the isolated antiprolifera-
tive compounds were also tested and compared to determine
the correlation between the two activities.
MATERIALS AND METHODS
Materials The processed green tea leaves (Camellia
sinensis, Theaceae) were supplied by Saga Tea Experimental
Station, Ureshino, Saga Prefecture, Japan.
Extraction and Isolation The processed green tea
leaves (200 g) were extracted with hot water. The detailed
procedure for the fractionation of the extract and isolation of
the constituens is shown in Chart 1.
Cells MK-1 cells were provided by Prof. M. Katano,
Faculty of Medicine, Kyushu University.
Determination of Antiproliferative Activity Inhibition
of cellular growth was estimated using the 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
described by Mosmann.17)
Measurement of DPPH Radical Scavenging Activity by
ESR The DPPH (1,1-diphenyl-2-picrylhydrazyl) radical
scavenging activity of the test sample was estimated by ESR,
according to the method of Tateyama et al.18)
RESULTS AND DISCUSSION
Results of the activity-guided fractionation of green tea
extract and the isolation of constituents are summarized in
Chart 1. First, the green tea extract was divided into three
fractions (Frs. 1—3) by Diaion HP-20 column chromatogra-
phy. The latter two fractions (Frs. 2, 3) showed potent an-
tiproliferarive activity, while Fr. 1, including sugars, amino
acids, and so on, was negative.
Sephadex LH-20 column chromatography of Fr. 2, fol-
lowed by reversed-phase silica gel chromatography (YMC
gel-AQ), yielded compounds 2 and 4. Fraction 3, which
showed potent activity, was further fracionated into four sub-
fractions (Frs. 3-1—3-4). As shown in Chart 1, Fr. 3-1 which
contained caffeine exhibited no activity. Fraction 3-2 showed
less potent activity, while Frs. 3-3 and 3-4 showed potent ac-
tivity. Repeated column chromatography of Fr. 3-3 by YMC
gel-AQ gave compounds 1 and 2. Similarly, Fr. 3-4 gave
compounds 3, 5 and 6. The less active fraction (Fr. 3-2) was
also subjected to YMC gel-AQ chromatography to afford
compounds 7, 8 and 9. Compounds 1—8 were identified as
epicatechin,19) epigallocatechin,19) epigallocatechin gallate,19)
gallocatechin,19) epicatechin gallate,19) gallocatechin gallate,19)
kaempferol 3-O-glucosyl-(1→3)-rhamnosyl-(1→6)-galacto-
∗ To whom correspondence should be addressed. e-mail: kinjojun@fukuoka-u.ac.jp © 2002 Pharmaceutical Society of Japan
Activity-Guided Fractionation of Green Tea Extract with Antiproliferative
Activity against Human Stomach Cancer Cells1)
Junei KINJO,*,a Tsuneatsu NAGAO,a Takashi TANAKA,b Gen-ichiro NONAKA,c Masafumi OKAWA,d
Toshihiro NOHARA,d and Hikaru OKABEa
a Faculty of Pharmaceutical Sciences, Fukuoka University; 8–19–1 Nanakuma, Jonan-ku, Fukuoka 814–0180, Japan:
b School of Pharmaceutical Sciences, Nagasaki University; 1–14 Bunkyomachi, Nagasaki 852–8521, Japan: c Usaien
Pharm. Co., Ltd.; 1–3–17 Zaimoku, Saga 840–0055, Japan: and d Faculty of Pharmaceutical Sciences, Kumamoto
University; 5–1 Oe-honmachi, Kumamoto 862–0973, Japan. Received March 4, 2002; accepted May 16, 2002
Epidemiological studies have suggested that the consumption of green tea provides protection against stom-
ach cancer. Fractionation of green tea extract, guided by antiproliferative activity against human stomach cancer
(MK-1) cells, has resulted in the isolation of six active flavan-3-ols, epicatechin (EC), epigallocatechin (EGC), epi-
gallocatechin gallate (EGCg), gallocatechin (GC), epicatechin gallate (ECg), gallocatechin gallate (GCg), to-
gether with inactive glycosides of kaempferol and quercetin. Among the six active flavan-3-ols, EGCg and GCg
showed the highest activity, EGC, GC, ECg followed next, and the activity of EC was lowest. These data suggest
that the presence of the three adjacent hydroxyl groups (pyrogallol or galloyl group) in the molecule would be a
key factor for enhancing the activity. Since reactive oxygen species play an important role in cell death induction,
radical scavenging activity was evaluated using the DPPH (1,1-diphenyl-2-picrylhydrazyl) radical. The order of
scavenging activity was ECg$EGCg$EGC$GC$EC. The compounds having a galloyl moiety showed more po-
tent activity. The contribution of the pyrogallol moiety in the B-ring to the scavenging activity seemed to be less
than that of the galloyl moiety.
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side20) and kaempferol 3-O-glucosyl-(1→3)-rhamnosyl-(1→
6)-glucoside,20) respectively, by comparison of their physical
data with those reported. Compound 9 was identified as a
mixture of quercetin 3-O-glucosyl-(1→3)-rhamnosyl-(1→6)-
galactoside and quercetin 3-O-glucosyl-(1→3)-rhamnosyl-
(1→6)-glucoside.20)
The antiproliferative activity of 1—9 was determined by
MTT assay, and their GI50 values are listed in Table 1.
All flavan-3-ols (1—6) showed potent activity. Com-
pounds 3 and 6 showed the highest activity of all, and 2, 4
and 5 showed moderate activity. Compound 1 showed the
lowest activity. Flavonol glycosides (7—9) did not show any
antiproliferative activity. Although there are some structural
similarities (the substitution patterns of the hydroxy groups
in A- and B-rings) between 1 and 9, compound 9 did not
show any activity. Therefore, the saturated C-ring, like fla-
van-3-ols, might influence the antiproliferative activity
against MK-1 cells.
In spite of a configurational difference at C-3, the GI50
value of 2 was the same as that of 4, and the GI50 values of 3
and 6 were equal, indicating that the configuration at C-3
would not affect the antiproliferative activity. The GI50 values
of 2, 4 and 5 (gallate of 1) were about one-third that of 1.
These data suggest that the presence of three adjacent hy-
droxyl groups (pyrogallol or galloyl group) in the molecule
would be a key factor for enhancing the activity. Finally, the
activity of 3, having a pyrogallol moiety in the B-ring and
galloyl moiety at C-3, was five times higher than that of 1.
Inoue et al. demonstrated that three adjacent phenolic hy-
droxyl groups of gallic acid should be essential to cytotoxic-
ity.21) They also disclosed that the cell death induced by gal-
lic acid was accompanied by internucleosomal DNA frag-
mentation characteristic of apoptosis.22) Hibasami et al. also
reported that the green tea extract and 3 showed both growth
inhibition and the induction of programmed cell death (apop-
tosis) against human stomach cancer KATO III cells.23) Since
reactive oxygen species play an important role in cell death
induction,14) the DPPH radical scavenging activity of some
active flavan-3-ols (1—5) was measured by ESR (Table 1).
Although 1—5 showed DPPH radical scavenging activity,
their potencies were different. Unexpectedly, the number of
hydoxyl group was not directly proportional to the activity.
The order of scavenging activity was 5$3$2$4$1. The
compounds having a galloyl moiety showed more potent ac-
tivity. The contribution of the pyrogallol moiety in B-ring to
the scavenging activity seemed to be less than that of the gal-
loyl moiety at C-3, although both moieties were a key factor
in enhancing the antiproliferative activity.
In conclusion, the water extract of green tea showed an-
tiproliferative activity against human stomach cancer (MK-1)
September 2002 1239
Table 1. Antiproliferative Activity (GI50, mM) against Human Stomach
Cancer (MK-1) Cells and DPPH Radical Scavenging Activity (IC50, mM)











Fig. 1. Antiproliferative Flavan-3-ols in Green Tea
Chart 1. Activity-Guided Fractionation of Green Tea Extract and Isolation of Active Principles
cells. By activity-guided fractionation, six flavan-3-ols (1—
6) were isolated as active principles. The structure–antipolif-
erative activity relationship was slightly correlated with that
of radical scavenging activity.
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